⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
JNJ News
Johnson & Johnson
Icotrokinra long-term results affirm promise of targeted oral peptide with high rates of durable skin clearance and favorable safety profile in difficult-to-treat scalp and genital psoriasis
prnewswire.com
JNJ
TECVAYLI® plus DARZALEX FASPRO® combination regimen significantly improves progression-free survival and overall survival versus standard of care
prnewswire.com
JNJ
Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2025
businesswire.com
JNJ
Johnson & Johnson Reports Q3 2025 Results; Raises 2025 Sales Outlook
businesswire.com
JNJ
Johnson & Johnson Announces Intent to Separate Its Orthopaedics Business
businesswire.com
JNJ
Johnson & Johnson recommends shareholders reject “mini-tender” offer by Tutanota
businesswire.com
JNJ
Johnson & Johnson to highlight breadth of its major depressive disorder portfolio at 2025 ECNP Congress
prnewswire.com
JNJ
Johnson & Johnson to Participate in the UBS Global Healthcare Conference
businesswire.com
JNJ
Johnson & Johnson Unveils New Data Demonstrating Superior Clarity of Vision and Comfort of ACUVUE OASYS MAX 1-Day for ASTIGMATISM, and MULTIFOCAL for ASTIGMATISM Contact Lenses
prnewswire.com
JNJ
TREMFYA® (guselkumab) is first and only IL-23 inhibitor to demonstrate sustained clinical and endoscopic outcomes with a fully subcutaneous regimen through 48 weeks in ulcerative colitis
prnewswire.com
JNJ